Search
Selected Filter
Displaying 191–200 of 493 news results
-
In the Press
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Research NewsMore details from the clinical trial will be reported at a later date
-
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
Research NewsThe company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
Research News
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Research NewsGene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Research NewsCellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
Foundation NewsThe project will help identify outcome measures for future clinical trials of potential USH1F therapies.
-
Foundation Fighting Blindness Appoints Claire M. Gelfman, Ph.D. as Chief Scientific Officer
Foundation NewsDr. Gelfman brings over twenty years of successful ophthalmic research and development experience to the Foundation executive team.
-
SparingVision to Acquire Therapy for Resurrecting Dormant Cones for Vision Restoration
Research NewsThe gene-agnostic approach shows promise for people with late-stage RP and related diseases.
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Research NewsDevelopment of the emerging gene therapy is being funded by the Foundation’s RD Fund
.png)
